894 related articles for article (PubMed ID: 21332446)
1. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA
Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
6. Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2010 Aug; 80(3):396-401. PubMed ID: 20417187
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).
Irwin N; Gault VA; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR; O'Harte FP
Biol Chem; 2005 Jul; 386(7):679-87. PubMed ID: 16207089
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
Irwin N; McClean PL; Cassidy RS; O'harte FP; Green BD; Gault VA; Harriott P; Flatt PR
Diabetes Metab Res Rev; 2007 Oct; 23(7):572-9. PubMed ID: 17315241
[TBL] [Abstract][Full Text] [Related]
9. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
10. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
11. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
[TBL] [Abstract][Full Text] [Related]
12. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
Pathak V; Vasu S; Gault VA; Flatt PR; Irwin N
Diabetologia; 2015 Sep; 58(9):2144-53. PubMed ID: 26048235
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
Pathak V; Vasu S; Flatt PR; Irwin N
Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
[TBL] [Abstract][Full Text] [Related]
14. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
15. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
16. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
17. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
18. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
19. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
20. Novel extrapancreatic effects of incretin.
Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
